Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

16 févr. 2016 07h00 HE | Source: Lumos Pharma, Inc.

NewLink Genetics to Participate in Three Upcoming Investor Conferences

AMES, Iowa, Feb. 16, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology...
12 févr. 2016 07h00 HE | Source: Lumos Pharma, Inc.

NewLink Genetics to Host Its Fourth Quarter and Year End 2015 Financial Results Conference Call on February 29, 2016

AMES, Iowa, Feb. 12, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
02 févr. 2016 07h00 HE | Source: Lumos Pharma, Inc.

NewLink Genetics Corporation Announces Project to Develop New Treatment Options for the Zika Virus

AMES, Iowa, Feb. 02, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
22 janv. 2016 08h00 HE | Source: Lumos Pharma, Inc.

NewLink Genetics Presents Phase 1b Data of Indoximod in Combination With Gemcitabine/Nab-Paclitaxel for Patients With Metastatic Pancreatic Cancer That Show Encouraging Durable Responses With Delayed Pattern

AMES, Iowa, Jan. 22, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
19 janv. 2016 17h00 HE | Source: Lumos Pharma, Inc.

NewLink Genetics Corporation to Present Phase 1b Data on Indoximod in Combination Therapy in Patients With Metastatic Pancreatic Cancer at ASCO GI

AMES, Iowa, Jan. 19, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
08 janv. 2016 07h00 HE | Source: Lumos Pharma, Inc.

NewLink Genetics Corporation Appoints Brian Wiley as Chief Commercial Officer

AMES, Iowa, Jan. 08, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
15 déc. 2015 07h00 HE | Source: Lumos Pharma, Inc.

NewLink Genetics Corporation Completes Enrollment of Phase 3 PILLAR Trial Evaluating Algenpantucel-L for Patients With Locally Advanced Pancreatic Cancer

AMES, Iowa, Dec. 15, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
10 déc. 2015 08h30 HE | Source: Lumos Pharma, Inc.

NewLink Genetics Corporation Presents Preliminary Safety Data From Randomized Phase 2 Trial of Indoximod, an IDO Pathway Inhibitor, at San Antonio Breast Cancer Symposium

AMES, Iowa and SAN ANTONIO, Dec. 10, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and...
10 déc. 2015 07h00 HE | Source: Lumos Pharma, Inc.

NewLink Genetics Corporation Reaches Enrollment Goal for Randomized Phase 2 Trial of Indoximod for Patients With Metastatic Breast Cancer

AMES, Iowa, Dec. 10, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
27 nov. 2015 07h00 HE | Source: Lumos Pharma, Inc.

NewLink Genetics to Present at the 27th Annual Piper Jaffray Healthcare Conference

AMES, Iowa, Nov. 27, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...

Page précédente

Page suivante